Cited by 643Prostate Cancer Treatment and ResearchChromatin Remodeling and CancerHormonal and reproductive studies

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Open access

Watson, Philip A., Chen, Yinan F., Balbas, Minna D., Wongvipat, John, Socci, Nicholas D., Viale, Agnes, Kim, Kwanghee, Sawyers, Charles L.·2010·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1012443107PMC PMC2947883

Open this paper in CoChat — free account

Abstract

Androgen receptor (AR) splice variants lacking the ligand binding domain (ARVs), originally isolated from prostate cancer cell lines derived from a single patient, are detected in normal and malignant human prostate tissue, with the highest levels observed in late stage, castration-resistant prostate cancer. The most studied variant (called AR-V7 or AR3) activates AR reporter genes in the absence of ligand and therefore, could play a role in castration resistance. To explore the range of potential ARVs, we screened additional human and murine prostate cancer models using conventional and next generation sequencing technologies and detected several structurally diverse AR isoforms. Some, like AR-V7/AR3, display gain of function, whereas others have dominant interfering activity. We also find that ARV expression increases acutely in response to androgen withdrawal, is suppressed by testosterone, and in some models, is coupled to full-length AR (AR-FL) mRNA production. As expected, constitutively active, ligand-independent ARVs such as AR-V7/AR3 are sufficient to confer anchorage-independent (in vitro) and castration-resistant (in vivo) growth. Surprisingly, this growth is blocked by ligand binding domain-targeted antiandrogens, such as MDV3100, or by selective siRNA silencing of AR-FL, indicating that the growth-promoting effects of ARVs are mediated through AR-FL. These data indicate that the increase in ARV expression in castrate-resistant prostate cancer is an acute response to castration rather than clonal expansion of castration or antiandrogen-resistant cells expressing gain of function ARVs, and furthermore, they provide a strategy to overcome ARV function in the clinic.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.1012443107

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

TopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L. S., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,682
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Self-citation
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M., Efstathiou, E., Rathkopf, D. E., Shelkey, J., Yu, E. Y., Alumkal, J. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Self-citation
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
FXXLF and WXXLF Sequences Mediate the NH2-terminal Interaction with the Ligand Binding Domain of the Androgen Receptor
He, B., Kemppainen, J., & Wilson, E. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002807200 · Cited by 441
Molecular basis of androgen insensitivity
Brinkmann, A. O. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00466-x · Cited by 345

Show all 27 references

Sorted by citations

Items 101–200 of 643

Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management
Koo, K. M., Mainwaring, P. N., Tomlins, S. A., & Trau, M. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0178-2 · Cited by 109
Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
Amaral, T. M. S., Macedo, D., Fernandes, I., & Costa, L. (2012) · Prostate Cancer · doi:10.1155/2012/327253 · Cited by 117
Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer
Qu, F., Xie, W., Nakabayashi, M., Zhang, H., Jeong, S. H., Wang, X., Komura, K., Sweeney, C. J., Sartor, O. A., Lee, G. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1070 · Cited by 108
ARe we there yet? Understanding androgen receptor signaling in breast cancer
Michmerhuizen, A. R., Spratt, D. E., Pierce, L. J., & Speers, C. W. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00190-9 · Cited by 111
Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
Decker, K. F., Zheng, D., He, Y., Bowman, T. A., Edwards, J. R., & Li, J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks888 · Cited by 106
Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells
Fan, L., Zhang, F., Xu, S., Cui, X., Hussain, A., Fazli, L., Gleave, M. E., Dong, X., & Qi, J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802415115 · Cited by 107
Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer
Purushottamachar, P., Godbole, A. M., Gediya, L. K., Martin, M. S., Vasaitis, T. S., Kwegyir‐Afful, A. K., Ramalingam, S., Ateş‐Alagöz, Z., & Njar, V. C. O. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400048v · Cited by 105
In vitro model systems to study androgen receptor signaling in prostate cancer
Sampson, N., Neuwirt, H., Puhr, M., Klocker, H., & Eder, I. E. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0401 · Cited by 105
Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenograftsin vivo
Kwegyir‐Afful, A. K., Ramalingam, S., Purushottamachar, P., Ramamurthy, V. P., & Njar, V. C. O. (2015) · Oncotarget · doi:10.18632/oncotarget.4578 · Cited by 102
Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression
Jin, R., Yamashita, H., Yu, X., Wang, J., Franco, O. E., Wang, Y., Hayward, S. W., & Matusik, R. J. (2014) · Oncogene · doi:10.1038/onc.2014.302 · Cited by 104
Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer
Han, W., Gao, S., Barrett, D. A., Ahmed, M., Han, D. G., Macoska, J. A., He, H. H., & Cai, C. (2017) · Oncogene · doi:10.1038/onc.2017.385 · Cited by 101
Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer
He, Y., Ji, L., Ye, Z., Hao, S., Wang, L., Kohli, M., Tindall, D. J., Li, B., Zhu, R., Wang, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1306 · Cited by 99
Expression of androgen receptor splice variants in clinical breast cancers
Hickey, T. E., Irvine, C. M., Dvinge, H., Tarulli, G. A., Hanson, A. R., Ryan, N. K., Pickering, M. A., Birrell, S. N., Hu, D. G., Mackenzie, P. I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6296 · Cited by 99
Androgen Receptor Signaling in Salivary Gland Cancer
Dalin, M. G., Watson, P. A., Ho, A. L., & Morris, L. G. T. (2017) · Cancers · doi:10.3390/cancers9020017 · Cited by 98
Androgen Receptor Splice Variant AR3 Promotes Prostate Cancer via Modulating Expression of Autocrine/Paracrine Factors
Sun, F., Chen, H.-G., Li, W., Yang, X., Wang, X., Jiang, R., Guo, Z., Chen, H., Huang, J., Borowsky, A. D., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.492140 · Cited by 96
Targeting Nuclear Receptors with PROTAC degraders
Flanagan, J. J., & Neklesa, T. K. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110452 · Cited by 98
New Therapeutic Approach to Suppress Castration-Resistant Prostate Cancer Using ASC-J9 via Targeting Androgen Receptor in Selective Prostate Cells
Lai, K., Huang, C.-K., Chang, Y., Chung, C., Yamashita, S., Li, L., Lee, S. O., Yeh, S., & Chang, C. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.10.029 · Cited by 93
Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer
Sharifi, N. (2013) · Endocrinology · doi:10.1210/en.2013-1466 · Cited by 96
Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer
Yang, Y., Jia, D., Kim, H., Elmageed, Z. Y. A., Datta, A., Davis, R., Srivastav, S., Moroz, K., Crawford, B. E., Moparty, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1606 · Cited by 89
Targeting the androgen receptor in prostate and breast cancer: several new agents in development
Proverbs-Singh, T. A., Feldman, J. L., Morris, M. J., Autio, K. A., & Traina, T. A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0543 · Cited by 90
ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer
Cai, L., Tsai, Y., Wang, P., Wang, J., Li, D., Fan, H., Zhao, Y., Bareja, R., Lu, R., Wilson, E. M., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.029 · Cited by 87
Intrinsic disorder in the androgen receptor: identification, characterisation and drugability
McEwan, I. J. (2011) · Molecular BioSystems · doi:10.1039/c1mb05249g · Cited by 93
The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer
Sprenger, C. C. T., & Plymate, S. R. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0177-y · Cited by 91
Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells
Krause, W. C., Shafi, A. A., Nakka, M., & Weigel, N. L. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.06.013 · Cited by 89
Androgens’ effects on cerebrovascular function in health and disease
Abi‐Ghanem, C., Robison, L. S., & Zuloaga, K. L. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00309-4 · Cited by 89
The Hippo Pathway in Prostate Cancer
Salem, O., & Hansen, C. G. (2019) · Cells · doi:10.3390/cells8040370 · Cited by 89
Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications
Mitani, Y., Rao, P. H., Maity, S. N., Lee, Y.-C., Ferrarotto, R., Post, J. C., Licitra, L. F., Lippman, S. M., Kies, M. S., Weber, R. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1746 · Cited by 85
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
Rathkopf, D. E., Patel, M. R., Choudhury, A. D., Rasco, D. W., Lakhani, N. J., Hawley, J. E., Srinivas, S., Aparicio, A. M., Narayan, V., Runcie, K. D., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.005 · Cited by 89
Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Li, Y., Yang, R., Henzler, C. M., Ho, Y., Passow, C. N., Auch, B., Carreira, S., Rodrigues, D. N., Bertan, C. M., Hwang, T. H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3023 · Cited by 82
Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer
Zhao, J., Ning, S., Lou, W., Yang, J. C., Armstrong, C. M., Lombard, A. P., D'Abronzo, L. S., Evans, C. P., Gao, A. C., & Liu, C. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0015 · Cited by 85
“Time” for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment
Miro, C., Docimo, A., Barrea, L., Verde, L., Cernea, S., Šojat, A. S., Marina, L., Docimo, G., Colao, A., Dentice, M., et al. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.03.003 · Cited by 85
Urine-based liquid biopsy: non-invasive and sensitive AR-V7 detection in urinary EVs from patients with prostate cancer
Woo, H., Park, J., Ku, J. Y., Lee, C. H., Sunkara, V., Ha, H. K., & Cho, Y. (2018) · Lab on a Chip · doi:10.1039/c8lc01185k · Cited by 85
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
Smith, R. L., Liu, M., Liby, T. A., Bayani, N., Bucher, E., Chiotti, K., Derrick, D. S., Chauchereau, A., Heiser, L. M., Alumkal, J. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78798-x · Cited by 83
CYP17A1 inhibitors in castration-resistant prostate cancer
Gomez, L., Kovac, J. R., & Lamb, D. J. (2015) · Steroids · doi:10.1016/j.steroids.2014.12.021 · Cited by 84
AR Variant ARv567es Induces Carcinogenesis in a Novel Transgenic Mouse Model of Prostate Cancer
Liu, G., Sprenger, C. C. T., Sun, S., Epilepsia, K. S., Haugk, K. L., Zhang, X., Coleman, I. M., Nelson, P. S., & Plymate, S. R. (2013) · Neoplasia · doi:10.1593/neo.13784 · Cited by 83
Androgen receptor: a potential therapeutic target for glioblastoma
Zalcman, N., Canello, T., Ovadia, H., Charbit, H., Zelikovitch, B., Mordechai, A., Fellig, Y., Rabani, S., Shahar, T., Lossos, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25007 · Cited by 80
Activation of β-Catenin Signaling in Androgen Receptor–Negative Prostate Cancer Cells
Wan, X., Liu, J., Lu, J.-F., Tzelepi, V., Yang, J., Starbuck, M. W., Diao, L., Wang, J., Efstathiou, E., Vazquez, E. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2521 · Cited by 79
Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
Ponnusamy, S., He, Y., Hwang, D., Thiyagarajan, T., Houtman, R., Bocharova, V., Sumpter, B. G., Fernandez, E. J., Johnson, D. L., Du, Z., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1458 · Cited by 81
Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma
Zhao, N., Wang, F., Ahmed, S., Liu, K., Zhang, C., Cathcart, S. J., DiMaio, D. J., Punsoni, M., Guan, B., Zhou, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.616625 · Cited by 81
Transcriptional Regulation in Prostate CancerPreprint
Labbé, D. P., & Brown, M. A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030437 · Cited by 80
Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues
Hu, D. G., Hickey, T. E., Irvine, C. M., Wijayakumara, D., Lu, L., Tilley, W. D., Selth, L. A., & Mackenzie, P. I. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0171-4 · Cited by 75
The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
Zheng, Z., Li, J., Liu, Y., Shi, Z., Xuan, Z., Yang, K., Xu, C., Bai, Y., Fu, M., Xiao, Q., et al. (2022) · Cancers · doi:10.3390/cancers14194877 · Cited by 77
Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells
Xu, D., Lin, T., Li, S., Da, J., Wen, X., Jiang, D., Chang, C., & Yeh, S. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.10.006 · Cited by 73
Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
Lallous, N., Dalal, K., Cherkasov, A. R., & Rennie, P. S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140612496 · Cited by 73
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
Antonarakis, E. S., & Armstrong, A. J. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.23 · Cited by 74
Androgen receptor‐related diseases: what do we know?
Shukla, G. C., Plaga, A. R., Shankar, E., & Gupta, S. (2016) · Andrology · doi:10.1111/andr.12167 · Cited by 77
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
Sartor, O. A. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-18 · Cited by 70
The Nuclear Hormone Receptor NHR-40 Acts Downstream of the Sulfatase EUD-1 as Part of a Developmental Plasticity Switch in Pristionchus
Kieninger, M. R., Ivers, N. A., Rödelsperger, C., Markov, G. V., Sommer, R. J., & Ragsdale, E. J. (2016) · Current Biology · doi:10.1016/j.cub.2016.06.018 · Cited by 70
Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor
Bryce, A. H., & Ryan, C. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.275 · Cited by 70
The Cistrome and Gene Signature of Androgen Receptor Splice Variants in Castration Resistant Prostate Cancer Cells
Ji, L., Lonergan, P. E., Nacusi, L. P., Wang, L., Schmidt, L. J., Sun, Z., der Steen, T. V., Boorjian, S. A., Kosari, F., Vasmatzis, G., et al. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.08.043 · Cited by 71
Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer
Shiota, M., Yokomizo, A., & Naito, S. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0232 · Cited by 71
The role of adrenal derived androgens in castration resistant prostate cancer
Barnard, M., Mostaghel, E. A., Auchus, R. J., & Storbeck, K. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105506 · Cited by 68
17β-Estradiol and testosterone in sarcopenia: Role of satellite cells
la Colla, A. B., Pronsato, L., Milanesi, L. M., & Vasconsuelo, A. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.07.011 · Cited by 73
Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors
Gryder, B. E., Akbashev, M. J., Rood, M. K., Raftery, E. D., Meyers, W. M., Dillard, P., Khan, S. A., & Oyelere, A. K. (2013) · ACS Chemical Biology · doi:10.1021/cb400542w · Cited by 67
Regulation of androgen receptor splice variant AR3 by PCGEM1
Zhang, Z., Zhou, N., Huang, J., Ho, T.-T., Zhu, Z., Qiu, Z., Zhou, X., Bai, C., Wu, F., Xu, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7139 · Cited by 68
AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
Sobhani, N., Neeli, P. K., D’Angelo, A., Pittacolo, M., Sirico, M., Galli, I. C., Roviello, G., & Nesi, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115515 · Cited by 70
Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone
Mohler, J. L., Titus, M. A., & Wilson, E. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0644 · Cited by 66
Proteolysis-Targeting Chimeras: Harnessing the Ubiquitin-Proteasome System to Induce Degradation of Specific Target Proteins
Coleman, K. G., & Crews, C. M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050430 · Cited by 72
The Impact of Point Mutations in the Human Androgen Receptor: Classification of Mutations on the Basis of Transcriptional Activity
Hay, C. W., & McEwan, I. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032514 · Cited by 70
Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance
Zhan, Y., Zhang, G., Wang, X., Qi, Y., Bai, S., Li, D., Ma, T., Sartor, O. A., Flemington, E. K., Zhang, H., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0236 · Cited by 66
Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer
Zhao, N., Peacock, S. O., Lo, C. H., Heidman, L. M., Rice, M. A., Fahrenholtz, C. D., Greene, A. M., Magani, F., Copello, V. A., Martinez, M. J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw4636 · Cited by 64
Cellular and Molecular Progression of Prostate Cancer: Models for Basic and Preclinical Research
Saranyutanon, S., Deshmukh, S. K., Dasgupta, S., Pai, S. G., Singh, S., & Singh, A. P. (2020) · Cancers · doi:10.3390/cancers12092651 · Cited by 65
Capsaicin causes inactivation and degradation of the androgen receptor by inducing the restoration of miR-449a in prostate cancer
Zheng, L. T., Chen, J., Ma, Z., Liu, W., YANG, F., YANG, Z., Wang, K., Wang, X., He, D., & Li, L. (2015) · Oncology Reports · doi:10.3892/or.2015.4055 · Cited by 64
Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
Liu, T., Wu, L. Y., Fulton, M. D., JOHNSON, J. M., & Berkman, C. E. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1649 · Cited by 63
Regulation of p53wt glioma cell proliferation by androgen receptor-mediated inhibition of small VCP/p97-interacting protein expression
Bao, D., Cheng, C., Lan, X., Xing, R., Chen, Z., Zhao, H., Sun, J., Wang, Y., Niu, C., Zhang, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15509 · Cited by 63
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer
Kirk, J. S., Schaarschuch, K., Dalimov, Z., Lasorsa, E., Ku, S., Ramakrishnan, S., Hu, Q., Azabdaftari, G., Wang, J., Пили, Р., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3077 · Cited by 65
AR-V7 and prostate cancer: The watershed for treatment selection?
Ciccarese, C., Santoni, M., Brunelli, M., Buti, S., Modena, A., Nabissi, M., Artibani, W., Martignoni, G., Montironi, R., Tortora, G., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.12.003 · Cited by 63
Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
Sun, R., Yan, B., Li, H., Ding, D., Wang, L., Pang, J., Ye, D., & Huang, H. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0285 · Cited by 65
Castration Induces Up-Regulation of Intratumoral Androgen Biosynthesis and Androgen Receptor Expression in an Orthotopic VCaP Human Prostate Cancer Xenograft Model
Knuuttila, M., Yatkin, E., Kallio, J., Savolainen, S., Laajala, T. D., Aittokallio, T. A., Oksala, R., Häkkinen, M. R., Keski‐Rahkonen, P., Auriola, S. O. K., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.04.010 · Cited by 65
Abiraterone in Prostate Cancer: A New Angle to an Old Problem
Stein, M. N., Goodin, S., & DiPaola, R. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1805 · Cited by 60
A New Trick of an Old Molecule: Androgen Receptor Splice Variants Taking the Stage?!
Guo, Z., & Qiu, Y. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.815 · Cited by 62
The Drosophila Accessory Gland as a Model for Prostate Cancer and Other Pathologies
WILSON, C. G., Leiblich, A., Goberdhan, D. C. I., & Hamdy, F. C. (2016) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2016.06.001 · Cited by 60
Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer
Liu, C., Armstrong, C. M., Lou, W., Lombard, A. P., Cucchiara, V., Gu, X., Yang, J. C., Nadiminty, N., Pan, C.-X., Evans, C. P., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0912 · Cited by 61
Advances in Androgen Receptor Targeted Therapy for Prostate Cancer
Ahmed, A., Ali, S. S., & Sarkar, F. H. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24456 · Cited by 60
Current status of liquid biopsies for the detection and management of prostate cancer
Lu, Y., Delijani, K., Mecum, A., & Goldkorn, A. (2019) · Cancer Management and Research · doi:10.2147/cmar.s170380 · Cited by 63
Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation
Duan, L., Chen, Z., Lu, J. K., Liang, Y., Wang, M., Roggero, C. M., Zhang, Q.-J., Gao, J., Fang, Y., Cao, J., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1004 · Cited by 59
Constitutive Activity of the Androgen Receptor
Chan, S. C., & Dehm, S. M. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-417197-8.00011-0 · Cited by 62
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer
Foley, C., & Mitsiades, N. (2016) · Hormones and Cancer · doi:10.1007/s12672-015-0239-9 · Cited by 62
Slug, a Unique Androgen-Regulated Transcription Factor, Coordinates Androgen Receptor to Facilitate Castration Resistance in Prostate Cancer
Wu, K., Gore, C., Yang, L., Fazli, L., Gleave, M. E., Pong, R.-C., Xiao, G., Zhang, L., Yun, E.-J., Tseng, S.-F., et al. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1360 · Cited by 57
Regulation of the Transcriptional Coactivator FHL2 Licenses Activation of the Androgen Receptor in Castrate-Resistant Prostate Cancer
McGrath, M. J., Binge, L. C., Sriratana, A., Wang, H., Robinson, P. A., Pook, D. W., Fedele, C. G., Brown, S., Dyson, J. M., Cottle, D. L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4520 · Cited by 58
Identification of a new androgen receptor (AR) co‐regulator BUD31 and related peptides to suppress wild‐type and mutated AR‐mediated prostate cancer growth via peptide screening and X‐ray structure analysis
Hsu, C.-L., Liu, J.-S., Wu, P.-L., Guan, H., Chen, Y., Lin, A.-C., Ting, H., Pang, S., Yeh, S.-D., Ma, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.009 · Cited by 58
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer
Knudsen, K. E., & Kelly, W. K. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.33 · Cited by 60
Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors
Gillis, J. L., Selth, L. A., Centenera, M. M., Townley, S. L., Sun, S., Plymate, S. R., Tilley, W. D., & Butler, L. M. (2013) · Oncotarget · doi:10.18632/oncotarget.975 · Cited by 59
NF‐κB and androgen receptor variant expression correlate with human BPH progression
Austin, D. C., Strand, D. W., Love, H. L., Franco, O. E., Jang, A., Grabowska, M. M., Miller, N. L., Hameed, O. M., Clark, P. E., Fowke, J. H., et al. (2015) · The Prostate · doi:10.1002/pros.23140 · Cited by 60
Emerging data on androgen receptor splice variants in prostate cancer
Cao, S., Zhan, Y., & Dong, Y. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0298 · Cited by 62
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts
Lam, H., Nguyen, H. M., Labrecque, M. P., Brown, L. G., Coleman, I. M., Gulati, R., Lakely, B., Sondheim, D., Chatterjee, P., Marck, B. T., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.05.042 · Cited by 60
Constitutively Active Androgen Receptor Variants Upregulate Expression of Mesenchymal Markers in Prostate Cancer Cells
Cottard, F., Asmane, I., Erdmann, É., Bergerat, J., Kurtz, J., & Céraline, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063466 · Cited by 57
Heat shock protein 70 inhibitors suppress androgen receptor expression in LNC aP95 prostate cancer cells
Kita, K., Shiota, M., Tanaka, M., Otsuka, A., Matsumoto, M., Kato, M., Tamada, S., Iwao, H., Miura, K., Nakatani, T., et al. (2017) · Cancer Science · doi:10.1111/cas.13318 · Cited by 55
Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy
Carpenter, V. J., Saleh, T., Lee, S. M., Murray, G. F., Reed, J. C., Souers, A. J., Faber, A. C., Harada, H., & Gewirtz, D. A. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114765 · Cited by 57
Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer
Ware, K. E., Somarelli, J. A., Schaeffer, D., Li, J., Zhang, T., Park, S., Patierno, S. R., Freedman, J. A., Foo, W., García-Blanco, M. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10476 · Cited by 56
Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer
Lv, S., Song, Q., Chen, G., Cheng, E., Chen, W., Cole, R. N., Wu, Z., Pascal, L. E., Wang, K., Wipf, P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141335 · Cited by 58
Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer
Fahrenholtz, C. D., Rick, F. G., Garcia, M. I., Zarándi, M., Cai, R., Block, N. L., Schally, A. V., & Burnstein, K. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323102111 · Cited by 55
The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance
Zarif, J. C., & Miranti, C. K. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.01.013 · Cited by 59
Androgen receptor plasticity and its implications for prostate cancer therapy
Snow, O., Lallous, N., Singh, K., Lack, N. A., Rennie, P. S., & Cherkasov, A. R. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.001 · Cited by 56
Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC)
Penning, T. M. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.05.010 · Cited by 56
Vav3 Enhances Androgen Receptor Splice Variant Activity and Is Critical for Castration-Resistant Prostate Cancer Growth and Survival
Peacock, S. O., Fahrenholtz, C. D., & Burnstein, K. L. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1165 · Cited by 55
The activity of the androgen receptor variant AR‐V7 is regulated by FOXO1 in a PTEN‐PI3K‐AKT‐dependent way
Mediwala, S. N., Sun, H., Szafran, A. T., Hartig, S. M., Sonpavde, G., Hayes, T. G., Thiagarajan, P., Mancini, M. A., & Marcelli, M. (2012) · The Prostate · doi:10.1002/pros.22566 · Cited by 57
The Extracellular Matrix Stiffening: A Trigger of Prostate Cancer Progression and Castration Resistance?
Luthold, C., Hallal, T., Labbé, D. P., & Bordeleau, F. (2022) · Cancers · doi:10.3390/cancers14122887 · Cited by 62
Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs
Han, D. G., Labaf, M., Zhao, Y., Owiredu, J. N., Zhang, S., Patel, K. J., Venkataramani, K., Steinfeld, J. S., Han, W., Li, M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci168649 · Cited by 56
Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer
Ferraldeschi, R., Pezaro, C. J., Karavasilis, V., & Bono, J. S. D. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-121211-091605 · Cited by 52

Authors: Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Human Oncology and Pathogenesis Program,
Bioinformatics Core,
University of California, Los Angeles (US)
Howard Hughes Medical Institute (US)
Corresponding author: Sawyers, Charles L.
ORCID: Watson, Philip A.
Socci, Nicholas D.
Viale, Agnes
Kim, Kwanghee
Sawyers, Charles L.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2010-09-07
Volume: 107
Issue: 39
Pages: 16759-16765
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1012443107
PMC: PMC2947883
OpenAlex: W2083926838
Cited by: 639
References: 27
Citations by year: 2026: 8 · 2025: 19 · 2024: 22 · 2023: 33 · 2022: 25 · 2021: 26 · 2020: 43 · 2019: 33 · 2018: 36 · 2017: 43 · 2016: 63 · 2015: 48 · 2014: 64 · 2013: 65 · 2012: 53
FWCI: 46.52
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
Prostate Cancer Foundation
University of Washington
National Cancer Institute
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords: androgen receptor splice variants, castration-resistant prostate cancer, AR-V7, ligand-independent receptor activation, full-length androgen receptor, androgen withdrawal, antiandrogen resistance, enzalutamide, anchorage-independent growth, siRNA knockdown, prostate cancer cell lines, androgen receptor isoforms
MeSH terms: Amino Acid Sequence, Androgens, Animals, Castration, Disease Models, Animal, Exons, Humans, Male, Molecular Sequence Data, Prostatic Neoplasms, Receptors, Androgen, RNA, Messenger, Gene Expression Regulation, Neoplastic, Alternative Splicing, Protein Structure, Tertiary, Sequence Analysis, Protein, Cell Line, Tumor, Mice, Androgen Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks